• Home
  •  / Amicus Therapeutics

Amicus Therapeutics

OverviewSuggest Edit

Amicus Therapeutics is a biopharmaceutical company developing oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. The Company is focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. It is initially targeting lysosomal storage disorders and continues to develop its pharmacological chaperone technology having built an intellectual property portfolio along with its robust clinical and preclinical pipeline.

TypePublic
Founded2002
HQCranbury Township, USMap
Websiteamicusrx.com
Employee Ratings2.9More
View Jobs (20)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)584(+15%)
Job Openings20
Revenue (FY, 2019)$182.2 M(+100%)
Share Price (Oct 2020)$18.5 (+3%)
Cybersecurity ratingAMore

Key People/Management at Amicus Therapeutics

John F. Crowley

John F. Crowley

Chairman and Chief Executive Officer
Daphne Quimi

Daphne Quimi

Chief Financial Officer
Bradley L. Campbell

Bradley L. Campbell

President and Chief Operating Officer
David Clark

David Clark

Chief People Officer
Ellen S. Rosenberg

Ellen S. Rosenberg

Chief Legal Officer
Jay A Barth

Jay A Barth

Chief Medical Officer
Show more

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Cranbury Township, Philadelphia, Northbridge, Pointe-Claire and in 8 other locations
Cranbury Township, US (HQ)
1 Cedarbrook Dr, Cranbury
Philadelphia, US
3675 Market St
Northbridge, AU
21 Dorset Rd
Pointe-Claire, CA
6500 TransCanada Service Rd, 4th Floor
Paris, FR
12 Place de la Défense
München, DE
Willy-Brandt-Platz
Show all (12)

Amicus Therapeutics Financials and Metrics

Amicus Therapeutics Revenue

Amicus Therapeutics's revenue was reported to be $182.24 m in FY, 2019
USD

Revenue (Q2, 2020)

62.4m

Gross profit (Q2, 2020)

55.7m

Gross profit margin (Q2, 2020), %

89.3%

Net income (Q2, 2020)

(52.5m)

EBIT (Q2, 2020)

(51.3m)

Market capitalization (23-Oct-2020)

4.8b

Closing stock price (23-Oct-2020)

18.5

Cash (30-Jun-2020)

164.6m

EV

4.7b
Amicus Therapeutics's current market capitalization is $4.8 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

21.4m18.4m363.0k1.2m5.0m36.9m91.2m182.2m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833.0k6.2m14.4m22.0m

Gross profit

4.1m30.7m76.8m160.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.0m5.8m7.8m10.6m39.0k456.0k475.0k293.0k2.1m4.2m7.2m10.9m16.7m21.3m20.6m34.0m44.1m48.8m60.5m62.4m

Cost of goods sold

344.0k775.0k1.1m1.8m2.6m3.1m4.3m4.1m5.4m5.6m6.6m6.7m

Gross profit

1.8m3.4m6.1m9.1m14.1m18.2m16.3m30.0m38.8m43.2m54.0m55.7m

Gross profit Margin, %

84%81%85%84%84%85%79%88%88%89%89%89%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

25.7m34.0m43.6m24.1m69.5m187.0m49.1m79.7m142.8m

Accounts Receivable

5.0m3.2m759.0k1.3m9.5m22.0m33.3m

Prepaid Expenses

5.9m2.3m5.5m2.9m2.6m19.3m16.6m20.0m

Inventories

3.4m4.6m8.4m14.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

25.8m22.8m24.5m28.9m24.3m26.7m23.5m30.0m27.5m41.9m19.7m28.8m249.0m19.4m23.5m63.7m33.1m44.8m37.4m64.1m114.3m73.3m201.8m96.3m220.6m166.3m123.2m164.6m

Accounts Receivable

2.0m3.8m4.3m7.2m3.2m1.3m1.0m2.1m38.0k475.0k293.0k864.0k1.9m3.8m6.0m10.8m15.1m14.2m23.0m28.7m33.7m40.6m43.0m

Prepaid Expenses

3.1m3.0m2.8m2.7m3.1m1.8m2.0m1.7m1.8m951.0k1.8m2.5m3.6m3.5m2.7m3.3m5.2m10.8m6.0m6.2m10.6m14.4m16.2m13.6m20.1m19.6m15.7m18.3m

Inventories

194.0k3.3m3.7m3.9m7.3m8.1m7.8m6.3m8.2m10.4m9.2m12.8m13.0m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(44.4m)(48.8m)(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)(349.0m)(356.4m)

Depreciation and Amortization

1.6m1.7m1.7m1.5m1.8m3.2m3.6m4.2m4.8m

Inventories

(3.7m)(897.0k)(4.2m)(5.1m)

Accounts Payable

1.4m(863.0k)(613.0k)6.2m15.5m7.1m12.6m17.1m46.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(26.0m)(35.7m)(13.1m)(22.5m)(38.8m)(17.5m)(32.8m)(47.4m)(15.9m)(30.6m)(47.7m)(24.3m)(51.4m)(89.2m)(43.7m)(94.7m)(141.4m)(55.0m)(103.1m)(214.8m)(49.9m)(111.8m)(270.9m)(120.3m)(204.8m)(266.7m)(88.9m)(141.4m)

Depreciation and Amortization

864.0k1.2m420.0k862.0k1.3m439.0k889.0k1.3m412.0k808.0k1.2m508.0k861.0k1.3m673.0k1.4m2.3m823.0k1.6m2.5m969.0k1.9m3.0m991.0k2.1m3.3m1.8m3.8m

Inventories

(207.0k)(3.5m)(243.0k)(351.0k)(3.4m)(3.3m)(3.4m)(2.0m)345.0k(1.9m)(2.0m)(251.0k)1.4m

Accounts Payable

(1.3m)(192.0k)(1.3m)(641.0k)(280.0k)(2.4m)173.0k(679.0k)(987.0k)(155.0k)1.2m(551.0k)459.0k14.1m(9.8m)(8.2m)(2.9m)(1.3m)(4.3m)13.0m(10.3m)(11.8m)3.7m(8.9m)12.5m8.7m(35.3m)(23.9m)
show all
USDQ2, 2011

Financial Leverage

2 x
Show all financial metrics

Amicus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about about our premium products
SecurityScorecard logo

Amicus Therapeutics Online and Social Media Presence

Amicus Therapeutics's Trends

Embed Graph

Amicus Therapeutics News and Updates

October 12, 2020

Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society

Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease
September 24, 2020

Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy

Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October
July 17, 2020

Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing

$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings
March 02, 2020

Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates

2019 Galafold Revenue Nearly Doubled to $182.2M
February 07, 2020

Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020

CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its de…
November 11, 2019

Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates

           3Q19 Galafold® (migalastat) Revenue of $48.8M  and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake
Show more

Amicus Therapeutics Blogs

May 08, 2020

Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders

Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders Content Import Fri, 05/08/2020 - 07:00 Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders May 8, 2020 at 7:00 AM EDT This release is a backfill from a News Wire …
May 07, 2020

Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions, On Track to Achieve 2020 Revenue Guidance of $250M-$260M AT-GAA in Late-Onset Pompe Disease Granted Rolling BLA Submission by U.S. FDA CLN3 Batten Disease Gene Therapy Granted Fast Track
May 06, 2020

Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting Matthew.Callan… Wed, 05/06/2020 - 07:01 Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting …
April 24, 2020

Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020

Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 Matthew.Callan… Fri, 04/24/2020 - 07:00 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 April 24, 2020 at 7:00 AM EDT This release is a back…
March 23, 2020

Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees Content Import Mon, 03/23/2020 - 07:01 Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and …
March 05, 2020

Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia

Significantly Expands Company’s R&D Capabilities to Advance Industry’s Largest Portfolio of Rare Disease Gene Therapy Programs State of the Art 75,000 Sq. Ft. Research Facility Across From University of Pennsylvania Strengthens Collaboration with Wilson Lab CRANBURY, N.J.
Show more

 Amicus Therapeutics Frequently Asked Questions

  • When was Amicus Therapeutics founded?

    Amicus Therapeutics was founded in 2002.

  • Who are Amicus Therapeutics key executives?

    Amicus Therapeutics's key executives are John F. Crowley, Daphne Quimi and Bradley L. Campbell.

  • How many employees does Amicus Therapeutics have?

    Amicus Therapeutics has 584 employees.

  • What is Amicus Therapeutics revenue?

    Latest Amicus Therapeutics annual revenue is $182.2 m.

  • What is Amicus Therapeutics revenue per employee?

    Latest Amicus Therapeutics revenue per employee is $312.1 k.

  • Who are Amicus Therapeutics competitors?

    Competitors of Amicus Therapeutics include Modis Therapeutics, Sanofi Genzyme and PhaseBio Pharmaceuticals.

  • Where is Amicus Therapeutics headquarters?

    Amicus Therapeutics headquarters is located at 1 Cedarbrook Dr, Cranbury, Cranbury Township.

  • Where are Amicus Therapeutics offices?

    Amicus Therapeutics has offices in Cranbury Township, Philadelphia, Northbridge, Pointe-Claire and in 8 other locations.

  • How many offices does Amicus Therapeutics have?

    Amicus Therapeutics has 12 offices.